A Phase 3 interventional study of Panzyga and Placebo in Pediatric Acute-Onset Neuropsychiatric Syndrome, sponsored by Octapharma. Completed at 12 sites in 3 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-01-07.
Sponsored by Octapharma · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A Superiority Study To Compare The Effect of Panzyga Versus Placebo in Patients with Pediatric Acute-onset Neuropsychiatric Syndrome
Octapharma is the lead sponsor of 71 studies on the registry; 8 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 16 (94%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Confirmed diagnosis of moderate to severe PANS with prominent and stable obsessive-compulsive disorder (OCD) symptoms (i.e. Clinical Global Impression (CGI)-Severity-OCD rating of ≥ 4 or higher on 2 ratings without a change of more than 1 unit between measurements) based on the following criteria:
Concurrent presence of additional neuropsychiatric symptoms, with similarly severe and acute onset, from at least two of the following seven categories, that are not better explained by a known neurologic or medical disorder, such as Sydenham chorea (SC), systemic lupus erythematosus, Tourette disorder, or other:
Patients who will additionally meet the following optional inclusion criteria will be identified as patients with Pediatric neuropsychiatric disorders associated with streptococcal infection (PANDAS):
Exclusion Criteria
a. In patients with relapsing episodes: Onset of initial PANS episode more than 24 months prior to first IMP treatment.
b. In patients with relapsing episodes: Absence of significant improvement and stabilization between the episodes according to investigator's judgment.
to receiving intravenous immunoglobulin (IVIG), including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Panzyga 10% IVIG
Biological: Panzyga
Placebo
Other: Placebo
Panzyga 10% IVIG
Placebo
Percentage Change in CY-BOCS Score From Baseline to Week 9
The primary endpoint of this study was the percentage change of neuropsychiatric symptomatology and behavior in PANS patients determined by clinician-rated Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) score. The CY-BOCS scale score is a clinician-rated, semi-structured interview for rating the presence or absence, as well as the severity of obsessive-compulsive symptoms. The CY-BOCS yields a total obsession score, a total compulsion score and combined total score (minimum total CY-BOCS score=0, maximum total CY-BOCS score=40). The mean percentage change in the total CY-BOCS score from Baseline to Week 9 was calculated and compared between Panzyga and Placebo treatment to demonstrate superiority. A value of 0 means there was no change from baseline to week 9. Negative values indicate a worse outcome. Positive values mean a better outcome.
Time frame: 9 Weeks
Percentage Change in Total CY-BOCS Score From Week 9 to Week 18 Within the (Panzyga - Placebo) Treatment Sequence Group
The CY-BOCS scores at the end of the follow up period were compared with the Week 9 scores to examine the durability of any clinical benefit following Panzyga treatment in the first 9-week treatment period and whether there was any worsening after crossing over to placebo treatment. The CY-BOCS scale score is a clinician-rated, semi-structured interview for rating the presence or absence, as well as the severity of obsessive-compulsive symptoms. The CY-BOCS yields a total obsession score, a total compulsion score and combined total score (minimum total CY-BOCS score=0, maximum total CY-BOCS score=40). The mean percentage change of the total CY-BOCS score at Week 18 to the Week 9 score was calculated within the (Panzyga - Placebo) treatment sequence group. A value of 0 means there was no change from Week 9 to Week 18. Negative values indicate a worse outcome. Positive values mean a better outcome.
Time frame: 9 Weeks (Week 9 to Week 18)
Clinical Global Impression - Improvement (CGI-I) Score at Week 9
The CGI-I rating scale was used to assess behavioral changes in PANS patients. The Clinical Global Impression - Improvement scale (CGI-I) is a 7-point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention and is rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. The mean CGI-I scores at Week 9 were compared between Panzyga and placebo treatment.
Time frame: 9 Weeks
Patients With PANS Improvement From Baseline to Week 9
The percentage of patients who showed PANS improvement was measured by Clinical Global Impression - Improvement (CGI-I) rating. "The Clinical Global Impression - Improvement is a 7-point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a Baseline state at the beginning of the intervention and is rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse." PANS improvement was defined as a CGI-I rating of 1 (Very much Improved), 2 (Much improved), or 3 (Minimally Improved). The percentages of improved patients at Week 9 were compared to baseline between Panzyga and placebo treatment.
Time frame: 9 Weeks
| Milestone | Placebo - Panzyga | Panzyga - Placebo |
|---|---|---|
| Started | 37 | 34 |
| Completed | 36 | 28 |
| Not completed | 1 | 6 |
| Milestone | Placebo - Panzyga | Panzyga - Placebo |
|---|---|---|
| Started | 36 | 28 |
| Completed | 32 | 28 |
| Not completed | 4 | 0 |
The CY-BOCS scores at the end of the follow up period were compared with the Week 9 scores to examine the durability of any clinical benefit following Panzyga treatment in the first 9-week treatment period and whether there was any worsening after crossing over to placebo treatment. The CY-BOCS scale score is a clinician-rated, semi-structured interview for rating the presence or absence, as well as the severity of obsessive-compulsive symptoms. The CY-BOCS yields a total obsession score, a total compulsion score and combined total score (minimum total CY-BOCS score=0, maximum total CY-BOCS score=40). The mean percentage change of the total CY-BOCS score at Week 18 to the Week 9 score was calculated within the (Panzyga - Placebo) treatment sequence group. A value of 0 means there was no change from Week 9 to Week 18. Negative values indicate a worse outcome. Positive values mean a better outcome.
| Percentage Change at Week 18 to Week 9 | Panzyga - Placebo |
|---|---|
| Percentage Change in Total CY-BOCS Score From Week 9 to Week 18 Within the (Panzyga - Placebo) Treatment Sequence Group | 29.4 ± 42.84 |
The CGI-I rating scale was used to assess behavioral changes in PANS patients. The Clinical Global Impression - Improvement scale (CGI-I) is a 7-point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention and is rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. The mean CGI-I scores at Week 9 were compared between Panzyga and placebo treatment.
| score on a scale | Placebo - Panzyga | Panzyga - Placebo |
|---|---|---|
| Clinical Global Impression - Improvement (CGI-I) Score at Week 9 | 3.3 ± 1.19 | 2.6 ± 1.32 |
The primary endpoint of this study was the percentage change of neuropsychiatric symptomatology and behavior in PANS patients determined by clinician-rated Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) score. The CY-BOCS scale score is a clinician-rated, semi-structured interview for rating the presence or absence, as well as the severity of obsessive-compulsive symptoms. The CY-BOCS yields a total obsession score, a total compulsion score and combined total score (minimum total CY-BOCS score=0, maximum total CY-BOCS score=40). The mean percentage change in the total CY-BOCS score from Baseline to Week 9 was calculated and compared between Panzyga and Placebo treatment to demonstrate superiority. A value of 0 means there was no change from baseline to week 9. Negative values indicate a worse outcome. Positive values mean a better outcome.
| Percentage Change at Week 9 to Baseline | Placebo - Panzyga | Panzyga - Placebo |
|---|---|---|
| Percentage Change in CY-BOCS Score From Baseline to Week 9 | 12.1 ± 68.39 | 31.1 ± 40.68 |
The percentage of patients who showed PANS improvement was measured by Clinical Global Impression - Improvement (CGI-I) rating. "The Clinical Global Impression - Improvement is a 7-point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a Baseline state at the beginning of the intervention and is rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse." PANS improvement was defined as a CGI-I rating of 1 (Very much Improved), 2 (Much improved), or 3 (Minimally Improved). The percentages of improved patients at Week 9 were compared to baseline between Panzyga and placebo treatment.
| Participants | Placebo - Panzyga | Panzyga - Placebo |
|---|---|---|
| PANS Improvement YES | 19 | 24 |
| PANS Improvement NO | 17 | 5 |
Collected over 18 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Panzyga | 0/70 (0%) | 5/70 (7.1%) | 64/70 (91.4%) |
| Placebo | 0/37 (0%) | 1/37 (2.7%) | 26/37 (70.3%) |
| Placebo After Panzyga | 0/27 (0%) | 0/27 (0%) | 19/27 (70.4%) |
| Event | Panzyga | Placebo | Placebo After Panzyga |
|---|---|---|---|
| Respiratory Tract InfectionInfections and infestations | 0/70 | 1/37 | 0/27 |
| NauseaGastrointestinal disorders | 1/70 | 0/37 | 0/27 |
| VomitingGastrointestinal disorders | 1/70 | 0/37 | 0/27 |
| HypertransaminasaemiaHepatobiliary disorders | 1/70 | 0/37 | 0/27 |
| HeadacheNervous system disorders | 1/70 | 0/37 | 0/27 |
| Obsessive-compulsive DisorderPsychiatric disorders | 1/70 | 0/37 | 0/27 |
| HaematuriaRenal and urinary disorders | 1/70 | 0/37 | 0/27 |
| Event | Panzyga | Placebo | Placebo After Panzyga |
|---|---|---|---|
| HeadacheNervous system disorders | 57/70 | 11/37 | 3/27 |
| NauseaGastrointestinal disorders | 34/70 | 8/37 | 2/27 |
| VomitingGastrointestinal disorders | 32/70 | 2/37 | 2/27 |
| PyrexiaGeneral disorders | 30/70 | 8/37 | 3/27 |
| Oropharyngeal PainRespiratory, thoracic and mediastinal disorders | 4/70 | 7/37 | 1/27 |
| Upper Abdominal PainGastrointestinal disorders | 12/70 | 3/37 | 2/27 |
| FatigueGeneral disorders | 8/70 | 0/37 | 0/27 |
| Coombs direct test positiveInvestigations | 7/70 | 0/37 | 1/27 |
| Haemoglobin DecreasedInvestigations | 7/70 | 1/37 | 0/27 |
| DiarrhoeaGastrointestinal disorders | 6/70 | 2/37 | 1/27 |
| Age, Categorical(Participants) | Placebo - Panzyga | Panzyga - Placebo | Total |
|---|---|---|---|
| <=18 years | 37 | 34 | 71 |
| Between 18 and 65 years | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | Placebo - Panzyga | Panzyga - Placebo | Total |
|---|---|---|---|
| Mean | 9.8 ± 2.95 | 9.3 ± 2.52 | 9.5 ± 2.74 |
| Sex: Female, Male(Participants) | Placebo - Panzyga | Panzyga - Placebo | Total |
|---|---|---|---|
| Female | 19 | 11 | 30 |
| Male | 18 | 23 | 41 |
| Ethnicity (NIH/OMB)(Participants) | Placebo - Panzyga | Panzyga - Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 5 | 3 | 8 |
| Not Hispanic or Latino | 32 | 30 | 62 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Body Mass Index(kg/m^2) | Placebo - Panzyga | Panzyga - Placebo | Total |
|---|---|---|---|
| Mean | 18.99 ± 3.980 | 19.18 ± 4.755 | 19.08 ± 4.337 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2021 to primary completion in Aug 2024, 37 months.
Results were first posted in Jan 2026, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Panzyga
Pediatric acute-onset neuropsychiatric syndrome